TY - JOUR T1 - Altered increase in STAT1 expression and phosphorylation in severe COVID-19 JF - medRxiv DO - 10.1101/2021.08.13.21262006 SP - 2021.08.13.21262006 AU - Hector Rincon-Arevalo AU - Arman Aue AU - Jacob Ritter AU - Franziska Szelinski AU - Dmytro Khadzhynov AU - Daniel Zickler AU - Luisa Stefanski AU - Andreia C. Lino AU - Sixten Körper AU - Kai-Uwe Eckardt AU - Hubert Schrezenmeier AU - Thomas Dörner AU - Eva V. Schrezenmeier Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/13/2021.08.13.21262006.abstract N2 - The interferon pathway represents a key antiviral defense mechanism and is being considered as a therapeutic target in COVID-19. Both, substitution of interferon and blocking interferon signaling through JAK STAT inhibition to limit cytokine storms have been proposed. However, little is known so far about possible abnormalities in STAT signaling in immune cells during SARS-CoV-2 infection. In the current study, we investigated downstream targets of interferon signaling, including STAT1, pSTAT1 and 2 and IRF1, 7 and 9 by flow cytometry in 30 patients with COVID-19, 17 with mild and 13 with severe infection. We report an upregulation of STAT1 and IRF9 in mild and severe COVID-19 cases, which correlated with the IFN-signature assessed by Siglec-1 (CD169) expression on peripheral monocytes. Most interestingly, Siglec-1 and STAT1 in CD14+ monocytes and plasmablasts showed lower expression among severe COVID-19 cases compared to mild cases. Contrary to the baseline whole protein STAT1 expression, the phosphorylation of STAT1 was enhanced in severe COVID-19 cases, indicating a dysbalanced JAK STAT signaling that fails to induce transcription of interferon stimulated response elements (ISRE). This abnormality persisted after IFN-α and IFN-γ stimulation of PBMCs from patients with severe COVID-19. The data suggest impaired STAT1 transcriptional upregulation among severely infected patients which may represent a potential predictive biomarker and may allow stratification of patients for certain interferon-pathway targeted treatments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementES was funded by the Federal Ministry of Education and Research (BMBF) grant BCOVIT, 01KI20161. ES received a grant by the Berlin Institute of Health with the Charite Clinician Scientist Program funded by the Charite-Universitaetsmedizin Berlin and the Berlin Institute of Health. ALS is funded by a scholarship of the German Society of Rheumatology. HRA holds a scholarship of the COLCIENCIAS scholarship No. 727, 2015. The CAPSID trial was funded by the German Federal Ministry of Health (Bundesministerium fuer Gesundheit) to HS and SK. TD is grantholder oft the Deutsche Forschungsgemeinschaft grants KO 2270/7 1, KO-2270/4 1 (KK); Do491/7-5, 11 1, Transregio 130 TP24. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was carried out in accordance with the recommendations of the ethics' committees at the Charite University Hospital Berlin and University of Ulm with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on reasonable request. ER -